PAI-1 and t-PA/PAI-1 complex potential markers of fibrinolytic bleeding after cardiac surgery employing cardiopulmonary bypass

BMC Anesthesiology

Volumn 12, Issue , 2012, Pages

  Ozolina, Agnese ^a   Strike, Eva ^a,b   Jaunalksne, Inta ^a   Krumina, Angelika ^b   Bjertnaes, Lars J ^c,d   Vanags, Indulis ^b  

^a PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^b RIGA STRADINS UNIVERSITY   (Latvia)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Cardiac surgery; Fibrinolysis; Plasminogen activator inhibitor; Tissue plasminogen activator

Indexed keywords

BIOLOGICAL MARKER; D DIMER; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CHEST TUBE; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

EID: 84867899717     PISSN: None     EISSN: 14712253     Source Type: Journal    
DOI: 10.1186/1471-2253-12-27     Document Type: Article

References (30)

1. Jimenez Rivera JJ, Iribarren JL, Raya JM, Nassar I, Lorente L, Perez R, Brouard M, Lorenzo JM, Garrido P, Barrios Y, Diaz M, Alarco B, Martinez R, Mora ML. Factors associated with excessive bleeding in cardiopulmonary bypass patients: a nested case-control study. J Cardiothorac Surg 2007, 2:17. 10.1186/1749-8090-2-17, 1950484, 17425777.
2. Sniecinski RM, Chandler WL. Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg 2011, 113:1319-1333. 10.1213/ANE.0b013e3182354b7e, 22003219.
3. Dacey LJ, Munoz JJ, Baribeau YR, Johnson ER, Lahey SJ, Leavitt BJ, Quinn RD, Nugent WC, Birkmeyer JD, O'Connor GT. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998, 133:442-447. 10.1001/archsurg.133.4.442, 9565127.
4. Iribarren JL, Jimenez JJ, Hernandez D, Brouard M, Riverol D, Lorente L, de La Llana R, Nassar I, Perez R, Martinez R, Mora ML. Postoperative bleeding in cardiac surgery: the role of tranexamic acid in patients homozygous for the 5G polymorphism of the plasminogen activator inhibitor-1 gene. Anesthesiology 2008, 108:596-602. 10.1097/ALN.0b013e318167aecc, 18362590.
5. Kuepper F, Dangas G, Mueller-Chorus A, Kulka PM, Zenz M, Wiebalck A. Fibrinolytic activity and bleeding after cardiac surgery with cardiopulmonary bypass and low-dose aprotinin therapy. Blood Coagul Fibrinolysis 2003, 14:147-153. 10.1097/00001721-200302000-00005, 12632024.
6. Burzotta F, Iacoviello L, Di Castelnuovo A, Zamparelli R, D'Orazio A, Amore C, Schiavello R, Donati MB, Maseri A, Possati G, Andreotti F. 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study. J Thromb Thrombolysis 2003, 16:149-154.
7. Vaughan DE. Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol 2001, 87:18C-24C. 10.1016/S0002-9149(01)01509-0, 11334764.
8. Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008, 14:1255-1260. 10.1111/j.1365-2516.2008.01834.x, 19141166.
9. Kruithof EK. Plasminogen activator inhibitors-a review. Enzyme 1988, 40:113-121.
10. Chandler WL, Levy WC, Stratton JR. The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation 1995, 92:2984-2994. 10.1161/01.CIR.92.10.2984, 7586269.
11. Yavari M, Becker RC. Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. J Thromb Thrombolysis 2009, 27:95-104. 10.1007/s11239-007-0187-5, 18214639.
12. Paulitsch FS, Schneider D, Sobel BE, Rached R, Ramires J, Jatene F, Stolf N, Hueb W, Lopes NH. Hemostatic changes and clinical sequelae after on-pump compared with off-pump coronary artery bypass surgery: a prospective randomized study. Coron Artery Dis 2009, 20:100-105. 10.1097/MCA.0b013e3283219e8b, 19293667.
13. Untch BR, Jeske WP, Schwartz J, Botkin S, Prechel M, Walenga JM, Bakhos M. Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. Clin Appl Thromb Hemost 2008, 14:141-148. 10.1177/1076029607308869, 18160569.
14. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999, 16:9-13. 10.1016/S1010-7940(99)00134-7, 10456395.
15. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957, 17:237-246. 10.1159/000205234, 13434757.
16. Chandler WL, Fitch JC, Wall MH, Verrier ED, Cochran RP, Soltow LO, Spiess D. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 1995, 74:1293-1297.
17. Sirgo G, Morales P, Rello J. PAI-1 gene: pharmacogenetic association of 4G/4G genotype with bleeding after cardiac surgery-pilot study. Eur J Anaesthesiol 2009, 26:404-411. 10.1097/EJA.0b013e3283240412, 19521296.
18. Welsby IJ, Podgoreanu MV, Phillips-Bute B, Mathew JP, Smith PK, Newman MF, Schwinn DA, Stafford-Smith M, Perioperative G, Safety Outcomes Study Investigative T Genetic factors contribute to bleeding after cardiac surgery. J Thromb Haemost 2005, 3:1206-1212. 10.1111/j.1538-7836.2005.01337.x, 15892865, Safety Outcomes Study Investigative T.
19. Duggan E, O'Dwyer MJ, Caraher E, Diviney D, McGovern E, Kelleher D, McManus R, Ryan T. Coagulopathy after cardiac surgery may be influenced by a functional plasminogen activator inhibitor polymorphism. Anesth Analg 2007, 104:1343-1347. table of contents, 10.1213/01.ane.0000261267.28891.00, 17513622.
20. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991, 11:183-190. 10.1161/01.ATV.11.1.183, 1670989.
21. DeLoughery TG. Coagulation defects in trauma patients: etiology, recognition, and therapy. Crit Care Clin 2004, 20:13-24. 10.1016/S0749-0704(03)00089-7, 14979327.
22. Gaudino M, Zamparelli R, Andreotti F, Burzotta F, Iacoviello L, Glieca F, Benedett M, Maseri A, Schiavello R, Possati G. Normothermia does not improve postoperative hemostasis nor does it reduce inflammatory activation in patients undergoing primary isolated coronary artery bypass. J Thorac Cardiovasc Surg 2002, 123:1092-1100. 10.1067/mtc.2002.120709, 12063455.
23. Chandler W. The effects of cardiopulmonary bypass on fibrin formation and lysis: is a normal fibrinolytic response essential?. J Cardiovasc Pharmacol 1996, 27(Suppl 1):S63-S68.
24. Agren A, Kolmert T, Wiman B, Schulman S. Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate. Thromb Res 2007, 119:715-721. 10.1016/j.thromres.2006.06.014, 16905180.
25. Jankun J, Keck R, Selman SH, Skrzypczak-Jankun E. Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss. Int J Mol Med 2010, 26:501-504.
26. D'Angelo A, Kluft C, Verheijen JH, Rijken DC, Mozzi E, Mannucci PM. Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin Invest 1985, 15:308-312. 10.1111/j.1365-2362.1985.tb00277.x, 3938400.
27. Mannucci L, Gerometta PS, Mussoni L, Antona C, Parolari A, Salvi L, Biglioli P, Tremoli E. One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery. Effect of aprotinin. Thromb Haemost 1995, 73:356-361.
28. Nuttall GA, Henderson N, Quinn M, Blair C, Summers L, Williams BA, Oliver WC, Santrach PJ. Excessive bleeding and transfusion in a prior cardiac surgery is associated with excessive bleeding and transfusion in the next surgery. Anesth Analg 2006, 102:1012-1017. 10.1213/01.ane.0000198563.28246.00, 16551890.
29. Engles L. Review and application of serine protease inhibition in coronary artery bypass graft surgery. Am J Health Syst Pharm 2005, 62:S9-S14. 10.2146/ajhp050300, 16227196.
30. Edmunds LH. Managing fibrinolysis without aprotinin. Ann Thorac Surg 2010, 89:324-331. 10.1016/j.athoracsur.2009.10.043, 20103278.